Here, we aim to describe the tumor heterogeneity of KRAS mutant lung cancers and its immune-regulatory role, to report the efficacy with current immunotherapies, and to overview the therapeutic approaches targeting KRAS mutant tumors, other than KRAS G12C inhibitors. This evidence concerns the gene KRAS and lung carcinoma.